Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

130 Stories from Volunteers, Donors & Supporters

7

Professional with expertise in this field

Rating: 5

I have been a member for a number of years. I always look forward to receiving the MAPS Bulletin, which is filled with fascinating articles. This is science in the true sense of the word, that is, one that is entirely compatible with a religious point of view and a humanistic psychology. There is no other organization like this one. I'm proud to be a member.

Review from Guidestar

5

Professional with expertise in this field

Rating: 5

I did my PhD dissertation research on the psychospiritual effects of ayahuasca retreats. I had very interesting and positve results. I was pleased to be able to present my research at the recent MAPS conference to a large audience of professionals and lay persons. When used appropriately psychedelic medicines can have very positive therapeutic effects. MAPS is one of the few venues that is seriously looking at this.

Review from Guidestar

5

Professional with expertise in this field

Rating: 5

Without the ongoing progress of MAPS in the field of psychedelic studies and their commitment to providing unbiased education, the growing movement of medical use of entheogens would not be happening. Keep up the good work!

4

Professional with expertise in this field

Rating: 5

MAPS has played a key role in assisting Professor Lyle Kraker, University of Massachusetts at Amherst, seek a registration from the U.S. Drug Enforcement Administration to cultivate Cannabis for clinical research. This long-term project will enable numerous researchers in the U.S. to learn much more about the functioning of the cannabinoid system within the body, and the numerous functions which it regulates. Because of the politicized ostracism of Cannabis and cannabinoid research, MAPS project to create a source of Cannabis for research that is independent of the federal anti-drug bureaucracy is essential to promote basic science. MAPS has demonstrated the vision, competence, and determination to drive this project ahead. This is just one instance of its important work.

4

Professional with expertise in this field

Rating: 4

I attended the Maps psychedelic science conference in April and met people that helped me with my dissertation on gay and lesbian people's experience with ayahuasca. I attended presentations on the many uses of psychedelics and how they affect people and attended presentations on ayahuasca. the topic of my dissertation. I was able to meet participants and consult with experts. It was very useful and I eventually met the reader for my dissertation there.

4

Professional with expertise in this field

Rating: 5

MAPS is a great organization that helps fund and support research and puts together clinicians and researchers on this value of psychedelic studies and medical treatment. I found their recent conference in San Jose inspirational and hope that they continue to be supported.

Review from Guidestar

4

Professional with expertise in this field

Rating: 5

MAPS brings together an extraordinary mix of people with widely differing backgrounds, necessarily sharing only a common interest in the topic of psychoactive drugs. The organization acts as an advocate for some of those people, who might have otherwise had no voice at all. In other cases it allows individuals who might have acted on their own to instead cooperate to make a stronger statement. Though the topics MAPS addresses don't always find favor with governmental/business groups, MAPS always marches boldly forward, and combining a principled approach with a core of pragmatism quite skillfully. Bravo to Rick Doblin, and to all the members, associates and hangers-on of the MAPS community.

5

Professional with expertise in this field

Rating: 5

MAPS is unique. Its pioneering resources & research program provide a depth of quality information and debate that is unequalled anywhere else in the world. [1] MAPS volunteers represent the forefront of knowledge in this valuable territory of brain research. Posting a question to MAPS can provide state-of-the-art discussion and data that I could not have obtained elsewhere. [2] Crucially, MAPS makes its resources freely available (you do not need a membership subscription). Again, pioneering in the belief that access to research should be open to all. I am indebted to MAPS and its volunteers for keeping me updated and informed for the past 15 years. ~ an invaluable rescource. Dr. Helena Watts, Imperial College London, UK.

4

Professional with expertise in this field

Rating: 5

I know MAPS and the President Rick Doblin since 1990 and I´m amazed how successful MAPS is in providing research in the area of psychedelic medicine. Through steady effort and profound work with experts this is possible. It is very necessary to research these substances for certain areas where common medicine fails.

4

Professional with expertise in this field

Rating: 5

I was introduced to MAPS during research in Ibogaine Studies, and the Harm Reduction movement. Since then, I have joined as a student member, and attended the recent conference in San Jose, CA. I am very impressed with the ability of this organization to pull together such highly talented individuals of such varied backgrounds, who are dedicated to opening the doors to developments that have been waiting in the wings for decades. Working together, using science and rigorous research methods, and on the basis of a social need and on spiritual and cultural expression, to further this important work. Thank you, MAPS, I hope to join you in this work one day soon!